HUP0104933A2 - MEK inhibitorok alkalmazása vírusellenes terápiában - Google Patents

MEK inhibitorok alkalmazása vírusellenes terápiában

Info

Publication number
HUP0104933A2
HUP0104933A2 HU0104933A HUP0104933A HUP0104933A2 HU P0104933 A2 HUP0104933 A2 HU P0104933A2 HU 0104933 A HU0104933 A HU 0104933A HU P0104933 A HUP0104933 A HU P0104933A HU P0104933 A2 HUP0104933 A2 HU P0104933A2
Authority
HU
Hungary
Prior art keywords
mek inhibitors
antiviral method
antiviral
curative
procedure
Prior art date
Application number
HU0104933A
Other languages
English (en)
Inventor
Alexander James Bridges
David Thomas Dudley
Stephen Joseph Gracheck
Annette Lynn Meyer
Alan Robert Saltiel
Judith Sebolt-Leopold
Original Assignee
Warner-Lambert Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Co. filed Critical Warner-Lambert Co.
Publication of HUP0104933A2 publication Critical patent/HUP0104933A2/hu
Publication of HUP0104933A3 publication Critical patent/HUP0104933A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A jelen tal lm ny t rgya MEK inhibitorok, kül"n"sen (I) vagy (II) ltalnos képletű vegyületek hat sos mennyiségének alkalmaz savírusfertőzések gyógyító vagy megelőző kezelésére szolg ló elj r sban. Ó
HU0104933A 1999-01-07 1999-12-21 Antiviral method using mek inhibitors HUP0104933A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11502699P 1999-01-07 1999-01-07
PCT/US1999/030484 WO2000040237A1 (en) 1999-01-07 1999-12-21 Antiviral method using mek inhibitors

Publications (2)

Publication Number Publication Date
HUP0104933A2 true HUP0104933A2 (hu) 2002-04-29
HUP0104933A3 HUP0104933A3 (en) 2003-12-29

Family

ID=22358895

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104933A HUP0104933A3 (en) 1999-01-07 1999-12-21 Antiviral method using mek inhibitors

Country Status (8)

Country Link
EP (1) EP1140067A1 (hu)
JP (1) JP2002534381A (hu)
AU (1) AU2203800A (hu)
CA (1) CA2358438A1 (hu)
HU (1) HUP0104933A3 (hu)
IL (1) IL144103A0 (hu)
WO (1) WO2000040237A1 (hu)
ZA (1) ZA200104000B (hu)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU59801A (sh) 1999-02-24 2005-07-19 F. Hoffmann-La Roche Ag. Fenil- i piridinil-derivati
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
CN1219753C (zh) * 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4-碘苯氨基苯氧肟酸的氧合酯
EP1201765A3 (en) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
AU2002249261A1 (en) * 2001-03-06 2002-09-19 Axxima Pharmaceuticals Ag Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
DE10138912A1 (de) * 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
HUE025767T2 (hu) 2002-03-13 2016-05-30 Array Biopharma Inc N3-alkilezett benzimidazol származékok mint MEK inhibitorok
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
KR101013932B1 (ko) 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 N-[(r)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
CN101006086B (zh) 2004-06-11 2010-09-29 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
SE0401969D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
ES2405785T3 (es) 2005-05-18 2013-06-03 Array Biopharma Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
EP2054418B1 (en) 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
CA2656618C (en) 2006-07-06 2014-08-26 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ATE493418T1 (de) 2006-07-06 2011-01-15 Array Biopharma Inc Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101605540A (zh) 2006-12-14 2009-12-16 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
JP5542282B2 (ja) 2007-07-05 2014-07-09 アレイ バイオファーマ、インコーポレイテッド Aktプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101801955B (zh) 2007-07-05 2013-05-08 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
AU2009204025B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2009204019B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
ES2399384T3 (es) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido fenoxibenzamidas sustituidas
WO2011047788A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491014A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011155898A1 (en) * 2010-06-11 2011-12-15 Wadell Goeran New antiviral compounds
EP2632899A1 (en) 2010-10-29 2013-09-04 Bayer Intellectual Property GmbH Substituted phenoxypyridines
RU2631240C2 (ru) 2011-04-01 2017-09-20 Дженентек, Инк. Комбинации соединений-ингибиторов акт и абиратерона, и способы применения
MX2013011333A (es) 2011-04-01 2014-04-16 Genentech Inc Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
US9566281B2 (en) * 2012-10-08 2017-02-14 Atriva Therapeutics Gmbh MEK inhibitors in the treatment of virus diseases
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
EP3043790B1 (en) 2013-09-11 2021-05-26 The Administrators of the Tulane Educational Fund Novel anthranilic amides and the use thereof
CA3078424A1 (en) * 2017-10-17 2019-04-25 Atriva Therapeutics Gmbh 2-(2-chloro-4-iodophenylamino)-3,4-difluorobenzoic acid for the treatment fo viral and bacterial infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
DE69836378T2 (de) * 1997-07-01 2007-10-11 Warner-Lambert Co. Llc Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
PT993439E (pt) * 1997-07-01 2004-12-31 Warner Lambert Co Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek

Also Published As

Publication number Publication date
IL144103A0 (en) 2002-05-23
CA2358438A1 (en) 2000-07-13
JP2002534381A (ja) 2002-10-15
ZA200104000B (en) 2002-08-16
HUP0104933A3 (en) 2003-12-29
WO2000040237A1 (en) 2000-07-13
EP1140067A1 (en) 2001-10-10
AU2203800A (en) 2000-07-24

Similar Documents

Publication Publication Date Title
HUP0104933A2 (hu) MEK inhibitorok alkalmazása vírusellenes terápiában
ES2160046A1 (es) Derivados pentapeptidicos.
ATE550320T1 (de) Antivirales mittel
NO20003233L (no) 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler
NZ303861A (en) Amino acid hydroxyethylamine sulphonamide derivatives as protease inhibitors
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
MX9706913A (es) Compuestos de bis-aminacido-hidroxietilamina-sulfonamida inhibidoresde proteasan retroviral, composiciones que los contienen y ek uso de los mismos.
AU2003291885A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
ATE229945T1 (de) Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
ATE283856T1 (de) Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
MX9706946A (es) Inhibidores de la proteasa retroviral de la hidroxietilaminosulfonamida de aminoacidos heterociclicocarbonilicos y uso de los mismos.
BR9607450A (pt) Inibidores de protease retroviral sulfonilalcanoilamino hidroxietilamino sulfonamida
NZ502988A (en) 5-Acetamido-4-amino-2-propionyloxy-6-isopropoxy-1-cyclohexene useful for treating influenza
BR0215067A (pt) Piridoquinoxalinas antivirais
YU44102A (sh) Ciklična kvaternerna amonijum jedinjenja
EA200100711A1 (ru) Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция
NO972905L (no) Tienoksasinon-derivater anvendelige som antivirusmidler
WO2002010124A3 (en) Salt forms of an hiv protease inhibitor
EP0355409A3 (en) Use of prolylendopeptidase inhibitors in the treatment of aids
HUP0004621A2 (hu) Egy HIV proteáz inhibitor fokozott orális felszívódást és biológiai hozzáférhetőséget mutató szulfátsója
HUP9902191A2 (hu) Az érképződést gátló anyag

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees